PharmiWeb Recruiter Blog

Thermo Fisher Scientific

Thermo Fisher Scientific's Clinical Research Business Named a Leader in Decentralized Clinical Trial Solutions by ISG

WILMINGTON, N.C., May 12, 2022 - The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been distinguished for industry leadership in digital and decentralized clinical trial solutions by Information Services Group (ISG), a leading global technology research and advisory firm. The business was recognized as an ISG Provider Lens Leader for its digital transformation services, including customer solutions for clinical development and patient engagement. This marks the second consecutive year the business has been acknowledged by ISG.

Read more
Abbott

Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials

  • New partnership will provide physician training to drive improved diversity in clinical trials
  • Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists
  • Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners

ABBOTT PARK, Ill., May 11, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.

Read more
Pfizer

Pfizer to Acquire Biohaven Pharmaceuticals

  • Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need
  • Expands Pfizer’s innovative Internal Medicine pipeline to drive enhanced growth through 2030 and beyond
  • Biohaven common shareholders will receive $148.50 per Biohaven share in cash, plus 0.5 of a share of a new publicly traded company that retains Biohaven’s non-CGRP pipeline compounds (“New Biohaven”)
  • Pfizer and Biohaven to hold analyst call at 10am ET today

NEW YORK & NEW HAVEN, CONN.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC® ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.

Read more
Modular Devices

Modular Devices Announces Acquisition of Cardiac Services Mobile

INDIANAPOLIS--(BUSINESS WIRE)--Modular Devices Acquisition, LLC (Modular Devices), a leading provider of mobile cath labs and mobile cleanrooms, today announced the acquisition of Cardiac Services Mobile, Inc. (Cardiac Services Mobile), a mobile cath lab company out of Nashville, TN that serves the US markets. The acquisition builds on Modular Devices’ position as the premier provider of mobile cardiac cath, peripheral vascular, electrophysiology (EP) and mobile CT labs for the rapidly growing US mobile imaging market.

Read more
ADVANZ

ADVANZ PHARMA to acquire Intercept’s business in Europe, Canada, and all other markets outside of the U.S.

  • Acquisition to strengthen ADVANZ PHARMA’s position as a partner of choice for commercialisation of specialty and hospital pharmaceuticals in Europe
  • Agreement includes ex-U.S. rights to commercialise orphan drug Ocaliva® for PBC, a progressive autoimmune disease affecting the liver, and the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S.

LONDON, May 05, 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, has signed an agreement with Intercept Pharmaceuticals, Inc. (“Intercept”) to acquire the majority of Intercept’s subsidiaries and operations in Europe, Canada, and all other markets outside of the U.S. This includes the ex-U.S. rights to commercialise Ocaliva® (obeticholic acid) for primary biliary cholangitis (PBC), a progressive autoimmune disease that damages the bile ducts in the liver. Intercept is a U.S.-based biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases.

Read more
Catalyst

Catalyst Clinical Research Acquires Aptus Clinical to Accelerate European Expansion, Broaden Client Services, and Enhance Patient Impact

The transaction capitalizes on the two company’s combined geographic strengths, complementary service offerings and therapeutic expertise to advance industry-leading research for improved patient outcomes.

WILMINGTON, N.C., ALDERLEY PARK, U.K, 4 May 2022 – Today, Catalyst Clinical Research, a market-leading provider of clinical research services, announced a strategic acquisition of Aptus Clinical to expand the geographic reach of the two companies, and to enhance patient access to advanced, life-changing therapies. Together, the two entities will become one multi-region clinical research organization with an accelerated growth trajectory in both the U.S. and Europe.

Read more
ALLUCENT

Pharm-Olam IS NOW ALLUCENT

  • Rebranding comes after a series of strategic acquisitions, most recently Pharm-Olam
  • Company’s newly combined services address clinical development and consulting needs of small and mid-sized biotechs
  • New name unites worldwide experienced workforce in its singular mission

CARY, N.C., May 3, 2022 – Global biopharmaceutical services leader, CATO SMS, today unveiled its new name, Allucent with bold branding to emphasize the company’s spotlight on serving the specialized needs of small and mid-sized biotech companies.

Read more